The registrational trial is expected to support the approval for Bavarian’s mpox/smallpox vaccine use in children 2-11 years ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to outbreaks of the ...

Bavarian Nordic’s MVA-BN vaccine showed equivalent antibody response and safety between teenagers and adults in an NIH study.

Results from this study could support an extension of the current approval of MVA-BN to include children from 2 years of age ...

One stock to keep an eye on is Bavarian Nordic (BVNRY). BVNRY is currently sporting a Zacks Rank of #2 (Buy), as well as an A grade for Value. Another notable valuation metric for BVNRY is its P/B ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Here is how Bavarian Nordic (BVNRY) and Dare Bioscience, Inc. (DARE) have performed compared to their sector so far this year.

(Reuters) -The World Health Organization said on Monday it had approved Bavarian Nordic's mpox vaccine for adolescents aged 12 to 17 years, an age group considered especially vulnerable to ...